Prudential Financial
TCRX icon

Prudential Financial’s TScan Therapeutics TCRX Stock Holding History

Prudential Financial’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29,800
Closed -$30.1K – 2586
2026
Q1 		$30.1K Buy
29,800
+5,400
+22% +$5.77K ﹤0.01% 2364
2025
Q4 		$24.4K Buy
24,400
+12,900
+112% +$18.7K ﹤0.01% 2188
2025
Q3 		$20.9K Buy
+11,500
New +$20.4K ﹤0.01% 2399
2025
Q2 		– Sell
-10,995
Closed -$15.2K – 2513
2025
Q1 		$15.2K Buy
10,995
+580
+6% +$1.25K ﹤0.01% 2268
2024
Q4 		$31.7K Buy
+10,415
New +$47.2K ﹤0.01% 2253
2023
Q1 		– Sell
-12,800
Closed -$20.9K – 2673
2022
Q4 		$20.9K Buy
12,800
+1,800
+16% +$4.41K ﹤0.01% 2565
2022
Q3 		$34K Buy
+11,000
New +$36K ﹤0.01% 2592

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Prudential Financial's TCRX Position: Q2 2026 in Review

Prudential Financial sold out of TScan Therapeutics (TCRX) in Q2 2026, closing a stake of 29,800 shares — an estimated $30.1K sold.

Prudential Financial first reported a position in TCRX in Q3 2022 and held it in 7 quarters. The position peaked at $34K in Q3 2022. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Prudential Financial reported no remaining TScan Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Prudential Financial sold 29,800 TScan Therapeutics shares in Q2 2026, an estimated $30.1K.
  • Prudential Financial first reported a position in TScan Therapeutics in Q3 2022 and held it in 7 quarters.
  • Prudential Financial's TScan Therapeutics position peaked at $34K in Q3 2022.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.